Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)
Experts applaud Amylyx for keeping its promise to withdraw ALS drug Relyvrio after trial failure
When Amylyx brought its ALS drug before the FDA in 2022, the biotech faced questions about what it would do if a crucial Phase 3 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
